ストックスクリーナーアプリを入手
0.8672
11.18%
0.0872
アフターアワーズ：
.90
0.0328
+3.78%
前日終値:
$0.78
開ける：
$0.86045
24時間の取引高:
673.87K
Relative Volume:
0.28
時価総額：
$140.33M
収益：
$400.57M
当期純損益:
$9.21M
株価収益率:
21.68
EPS:
0.04
ネットキャッシュフロー:
$146.36M
1週間 パフォーマンス:
+17.24%
1か月 パフォーマンス:
+28.78%
6か月 パフォーマンス:
-77.00%
1年 パフォーマンス:
-87.23%
1日の値動き範囲:
$0.8243
$0.8803
1週間の範囲:
$0.7346
$0.8803
52週間の値動き範囲:
$0.5271
$7.105
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
名前
Ironwood Pharmaceuticals Inc
セクター
電話
617-621-7722
住所
100 SUMMER STREET, SUITE 2300, BOSTON, MA
IRWD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
0.8672 | 126.22M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
153.45 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.75 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.58 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.61 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-15 | ダウングレード | Jefferies | Buy → Hold |
| 2025-04-15 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 開始されました | Leerink Partners | Market Perform |
| 2024-08-08 | ダウングレード | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 開始されました | Craig Hallum | Buy |
| 2023-12-14 | 開始されました | Wells Fargo | Overweight |
| 2023-11-09 | 開始されました | Jefferies | Buy |
| 2023-09-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-02 | 開始されました | CapitalOne | Overweight |
| 2022-04-22 | 開始されました | Piper Sandler | Overweight |
| 2020-09-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 開始されました | Northland Capital | Outperform |
| 2019-07-10 | 再開されました | Credit Suisse | Neutral |
| 2019-03-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | アップグレード | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | アップグレード | JP Morgan | Underweight → Neutral |
| 2018-11-07 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 開始されました | H.C. Wainwright | Sell |
| 2018-05-09 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2017-07-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 開始されました | Wells Fargo | Outperform |
| 2017-04-07 | 繰り返されました | Mizuho | Buy |
| 2017-02-22 | 繰り返されました | Barclays | Equal Weight |
| 2016-11-04 | 繰り返されました | Mizuho | Buy |
| 2016-10-24 | 繰り返されました | Wedbush | Neutral |
| 2016-10-10 | 繰り返されました | Mizuho | Buy |
| 2016-09-27 | 繰り返されました | WallachBeth | Hold |
すべてを表示
Ironwood Pharmaceuticals Inc (IRWD) 最新ニュース
What drives Ironwood Pharmaceuticals Inc. stock priceTriple-digit wealth increases - Autocar Professional
What analysts say about Ironwood Pharmaceuticals Inc. stockHigh-yield market plays - Autocar Professional
Is Ironwood Pharmaceuticals Inc. a good long term investmentRapid portfolio appreciation - jammulinksnews.com
Ironwood Pharmaceuticals Inc. Stock Analysis and ForecastFree Consultation - jammulinksnews.com
How the Irritable Bowel Syndrome (IBS) Treatment Market Will - openPR.com
How Ironwood Pharmaceuticals Inc. stock performs during market volatilityTop Gaining Low Risk Assets - Newser
What makes Ironwood Pharmaceuticals Inc. stock price move sharplyFast Moving Stock Alerts - Newser
Why Ironwood Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Confidence Trade Setups - Newser
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - The Globe and Mail
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, And Clinical Trial Landscape Analysis By Delveinsight Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, Abbvie/Neurocrine - MenaFN
Ironwood Pharmaceuticals appoints KPMG as new auditor, dismisses EY By Investing.com - Investing.com Nigeria
Ironwood Pharmaceuticals appoints KPMG as new auditor, dismisses EY - Investing.com
Investor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ironwood Pharmaceuticals, Inc.(NasdaqGS: IRWD) added to Russell 3000E Index - MarketScreener
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28% - simplywall.st
Ironwood Pharma Elects Directors at Annual Meeting - TipRanks
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Is A Good Stock To Invest In - Stocksregister
Ameriprise Financial Inc. Trims Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer - GlobeNewswire
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock By Investing.com - Investing.com India
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock - Investing.com Australia
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates - MSN
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call - MSN
Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Target Price at $4.78 - Defense World
Ironwood Pharmaceuticals Inc (IRWD) 財務データ
収益
当期純利益
現金流量
EPS
1.34%
大文字化:
|
ボリューム (24 時間):